Persistent Conflation of SARMs and Peptides in Vendor Marketing Materials: A Call for Accurate Categorization
Posted: Mon Apr 06, 2026 11:45 am
I will preface this by stating that I have been active in this research community for well over a decade and have, in that time, developed a reasonably high tolerance for the inevitable imprecision that accompanies discussions at the intersection of grey-market research chemistry and internet forums. However, I find myself genuinely frustrated by a trend that has accelerated considerably over the past two to three years, and I believe it warrants direct discussion.
An increasing number of vendors, both domestic and international, have begun marketing peptides and selective androgen receptor modulators under consolidated category headings, frequently listing compounds such as BPC-157, Ipamorelin, and Epithalon alongside RAD-140, LGD-4033, and Ostarine as though these represent equivalent classes of research compounds. They do not. Not remotely.
Peptides are short chains of amino acids that interact with specific receptors, enzymes, or signaling cascades through mechanisms entirely distinct from the androgen receptor binding and transcriptional modulation that characterizes SARMs. The pharmacokinetic profiles, the storage requirements, the reconstitution protocols, and critically, the regulatory and safety consideration frameworks are fundamentally different. Conflating them for commercial convenience does a genuine disservice to researchers who are attempting to design methodologically sound protocols.
What prompted this post specifically was an interaction I had last month with a vendor I will not name publicly but whose initials have appeared frequently in recommendation threads here. I placed an order for a research-grade lyophilized preparation of CJC-1295 without DAC, and what arrived was clearly mislabeled, based on the reconstituted solution behavior and the entirely anomalous results I observed when running standard verification procedures. When I contacted support, I was directed to a FAQ document that lumped dosing guidance for growth hormone secretagogues together with SARM cycle recommendations in a single document. The guidance cited no primary literature whatsoever and made assertions about half-lives that contradicted published pharmacokinetic data, including the work by Jetté et al. and subsequent analyses of GHRH analogue clearance rates.
This is not a minor inconvenience. Researchers relying on vendor-generated documentation as a substitute for reviewing actual literature are going to arrive at flawed conclusions and potentially compromised experimental designs.
I would strongly encourage the moderators of this forum to consider implementing some form of resource pinning that clearly delineates these compound classes, and I would ask that members apply pressure to vendors through purchase decisions and public feedback to demand categorically accurate product documentation. The research community is not well served by commercial convenience overriding biochemical accuracy.
An increasing number of vendors, both domestic and international, have begun marketing peptides and selective androgen receptor modulators under consolidated category headings, frequently listing compounds such as BPC-157, Ipamorelin, and Epithalon alongside RAD-140, LGD-4033, and Ostarine as though these represent equivalent classes of research compounds. They do not. Not remotely.
Peptides are short chains of amino acids that interact with specific receptors, enzymes, or signaling cascades through mechanisms entirely distinct from the androgen receptor binding and transcriptional modulation that characterizes SARMs. The pharmacokinetic profiles, the storage requirements, the reconstitution protocols, and critically, the regulatory and safety consideration frameworks are fundamentally different. Conflating them for commercial convenience does a genuine disservice to researchers who are attempting to design methodologically sound protocols.
What prompted this post specifically was an interaction I had last month with a vendor I will not name publicly but whose initials have appeared frequently in recommendation threads here. I placed an order for a research-grade lyophilized preparation of CJC-1295 without DAC, and what arrived was clearly mislabeled, based on the reconstituted solution behavior and the entirely anomalous results I observed when running standard verification procedures. When I contacted support, I was directed to a FAQ document that lumped dosing guidance for growth hormone secretagogues together with SARM cycle recommendations in a single document. The guidance cited no primary literature whatsoever and made assertions about half-lives that contradicted published pharmacokinetic data, including the work by Jetté et al. and subsequent analyses of GHRH analogue clearance rates.
This is not a minor inconvenience. Researchers relying on vendor-generated documentation as a substitute for reviewing actual literature are going to arrive at flawed conclusions and potentially compromised experimental designs.
I would strongly encourage the moderators of this forum to consider implementing some form of resource pinning that clearly delineates these compound classes, and I would ask that members apply pressure to vendors through purchase decisions and public feedback to demand categorically accurate product documentation. The research community is not well served by commercial convenience overriding biochemical accuracy.
its basically like when beauty companies slap "anti-aging" on literally everything including a bar of soap